Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Rhea-AI Summary

Agios Pharmaceuticals (Nasdaq: AGIO), a leader in cellular metabolism and PK activation therapies for rare diseases, has announced a conference call and live webcast scheduled for August 1, 2024, at 8:00 a.m. ET. The event will cover Agios' second quarter 2024 financial results and other business highlights. Investors and interested parties can access the live webcast under the 'Events & Presentations' section of Agios' website. A replay will be available for at least two weeks following the presentation.

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, August 1, 2024, at 8:00 a.m. ET to report its second quarter 2024 financial results and other business highlights.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Dan Budwick
1AB
dan@1abmedia.com  

FAQ

When will Agios Pharmaceuticals (AGIO) report its Q2 2024 financial results?

Agios Pharmaceuticals (AGIO) will report its second quarter 2024 financial results on August 1, 2024, during a conference call and live webcast at 8:00 a.m. ET.

How can investors access Agios Pharmaceuticals' (AGIO) Q2 2024 earnings call?

Investors can access Agios Pharmaceuticals' (AGIO) Q2 2024 earnings call via a live webcast under the 'Events & Presentations' section of the company's website at www.agios.com.

Will there be a replay available for Agios Pharmaceuticals' (AGIO) Q2 2024 earnings webcast?

Yes, a replay of Agios Pharmaceuticals' (AGIO) Q2 2024 earnings webcast will be archived on the company's website for at least two weeks following the presentation.

What is Agios Pharmaceuticals' (AGIO) primary focus in drug development?

Agios Pharmaceuticals (AGIO) is a leader in cellular metabolism and PK activation, focusing on pioneering therapies for rare diseases.